Charles River Laboratories International, Inc. ( CRL ) Nowojorska Giełda Papierów Wartościowych

Cena: 178.46 ( 6.26% )

Aktualizacja 07-24 19:23
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Diagnostics & Research
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Charles River Laboratories International, Inc., niekliniczna organizacja badań kontraktowych, zapewnia usługi odkrywania leków, rozwoju nieklinicznego i testowania bezpieczeństwa w Stanach Zjednoczonych, Europie, Kanadzie, Azji i Pacyfiku i na arenie międzynarodowej. Działa w trzech segmentach: modele i usługi badawcze (RMS), ocena odkrywania i bezpieczeństwa (DSA) oraz rozwiązania produkcyjne (produkcja). Segment RMS produkuje i sprzedaje szczepy modelu badań gryzoni oraz wyżywione przez cel szczury i myszy do użytku przez naukowców. Ten segment zapewnia również szereg usług, które pomagają swoim klientom w wspieraniu stosowania modeli badawczych w badaniach i badaniach nieklinicznych kandydatów na leki, w tym modele badawcze, genetycznie zmodyfikowane modele i usługi, rozwiązania insourcingowe i badania diagnostyki zwierząt badawczych. Segment DSA oferuje wczesne i in vivo usługi odkrywania w celu identyfikacji i walidacji nowych celów, związków chemicznych i przeciwciał poprzez dostarczanie nieklinicznych kandydatów na leki i terapeutyczne gotowe do oceny bezpieczeństwa; oraz usługi oceny bezpieczeństwa, takie jak toksykologia, patologia, farmakologia bezpieczeństwa, bioanaliza, metabolizm leków i usługi farmakokinetyczne. Segment produkcyjny zapewnia metody in vitro do konwencjonalnego i szybkiego testowania kontroli jakości sterylnych i niesterycznych produktów farmaceutycznych i produktów konsumenckich. Ten segment oferuje również wyspecjalizowane testy biologiczne, które są zlecane przez firmy farmaceutyczne i biotechnologiczne; oraz ptasie usługi szczepionek, które zapewniają żyzne jaja kurczaka bez patogenu (SPF), kurczaki SPF i produkty diagnostyczne stosowane do produkcji szczepionek. Firma świadczy również usługi operacyjne Vivarium dla klientów biofarmaceutycznych. Charles River Laboratories International, Inc. został założony w 1947 roku i ma siedzibę w Wilmington w stanie Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 20 400
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 97.8292
Ilość akcji: Brak danych
Debiut giełdowy: 2000-06-23
WWW: https://www.criver.com
CEO: Mr. James C. Foster J.D.
Adres: 251 Ballardvale Street
Siedziba: 01887 Wilmington
ISIN: US1598641074
Wskaźniki finansowe
Kapitalizacja (USD) 8 765 433 401
Aktywa: 8 003 842 000
Cena: 178.46
Wskaźnik Altman Z-Score: 2.6
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -297.4
Ilość akcji w obrocie: 98%
Średni wolumen: 1 031 160
Ilość akcji 49 115 700
Wskaźniki finansowe
Przychody TTM 4 060 916 000
Zobowiązania: 4 176 125 000
Przedział 52 tyg.: 91.86 - 254.15
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: -0.6
P/E branży: 30.3
Beta: 1.376
Raport okresowy: 2025-08-06
WWW: https://www.criver.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Joseph W. LaPlume Corporate Executive Vice President of Corporate Development & Strategy 928 357 1974
Mr. James C. Foster J.D. Chief Executive Officer, President & Chairman 2 663 827 1951
Ms. Flavia H. Pease Corporate Executive Vice President & Chief Financial Officer 1 656 005 1973
Ms. Birgit Girshick Corporate Executive Vice President & Chief Operating Officer 1 280 523 1970
Mr. William D. Barbo Corporate Executive Vice President of Community Relations 1 004 066 1961
Mr. Michael Gunnar Knell Corporate Senior Vice President & Chief Accounting Officer 0 1977
Mr. Mark Mintz Corporate Senior Vice President & Chief Information Officer 0 0
Todd Spencer Corporate Vice President of Investor Relations 0 0
Mr. Matthew L. Daniel Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer 0 0
Prof. Julie Frearson Ph.D. Corporate Senior Vice President & Chief Scientific Officer 0 0
Lista ETF z ekspozycją na akcje Charles River Laboratories International, Inc.
Symbol ETF Ilość akcji Wartość
VOO 1 454 707 197 301 910
SCYB 1 372 000 1 296 772
VB 1 290 038 174 967 853
JCPB 1 095 000 1 003 341
RSP 947 913 148 936 090
VBR 829 287 112 476 195
XHY.TO 785 000 1 022 236
IVV 596 600 91 816 685
SPY 593 928 91 810 892
FSYD 583 000 566 260
SIHY 550 000 505 043
BBHY 416 000 381 178
XLV 341 174 53 690 296
IBB 308 983 47 552 525
IEFA 224 603 6 321 953
GHYB 215 000 200 223
BBHY 183 000 177 572
IWR 173 996 26 777 961
VHT 153 586 20 830 869
DFAS 132 504 20 819 028
SCHM 130 212 20 458 909
VGK 125 447 2 948 356
CSSPX.MI 121 040 18 627 990
CSPX.L 121 040 18 627 990
GSPX.L 121 040 18 627 990
CSP1.L 121 040 18 627 990
SXR8.DE 121 040 18 627 990
CSPX.AS 121 040 18 627 990
IWD 111 222 17 117 124
WTV 89 865 13 335 966
SCHC 83 582 2 217 346
IVE 80 039 12 318 050
RSPH 79 520 12 494 182
SCHG 74 590 11 715 809
IWS 73 410 11 297 870
SPLG 72 402 11 025 999
VUAA.L 70 093 9 506 713
VUAA.MI 70 093 8 096 867
VUSA.MI 70 093 8 096 867
VUSD.L 70 093 9 506 713
VUSA.AS 70 093 8 096 867
VUSA.DE 70 093 8 096 867
VUSA.L 70 093 6 994 564
DFSV 64 260 10 096 531
DRDR.L 62 074 9 553 210
HEAL.L 62 074 9 553 210
2B78.DE 62 074 9 553 210
ITOT 61 030 9 392 476
EWSP.L 59 941 9 224 919
ISPE.L 59 941 9 224 919
FNDA 56 514 8 577 600
SPYV 55 053 8 492 173
SCHX 49 155 7 723 233
BBHY 43 000 40 365
DFUV 41 977 6 595 426
IUSV 40 528 6 237 192
JHMM 39 806 5 695 442
FMDE 39 106 6 158 803
DFAC 37 513 5 894 042
IWB 35 615 5 481 131
BBH 35 239 5 549 790
IUSN.DE 32 582 5 014 327
WSML.L 32 582 5 014 327
WLDS.L 32 582 5 014 327
SCZ 30 690 4 723 247
IXJ 28 267 4 350 338
VONV 27 441 3 721 822
IYH 26 769 4 119 686
SXRG.DE 24 196 3 723 744
CUS1.L 24 196 3 723 744
CUSS.L 24 196 3 723 744
CSUSS.MI 24 196 3 723 744
QDVG.DE 23 412 3 603 075
IHCU.L 23 412 3 603 075
IUHC.L 23 412 3 603 075
IUHE.AS 23 412 3 603 075
SPHB 21 542 3 384 679
BBMC 21 151 3 209 241
ESML 21 133 3 320 416
FHLC 21 098 3 322 724
XBB 20 000 0
XBB 20 000 0
IDUS.L 19 084 2 937 044
IUSA.L 19 084 2 937 044
IUSA.AS 19 084 2 937 044
IUSA.DE 19 084 2 937 044
IWV 13 971 2 150 187
RECS 13 921 2 187 267
XEF.TO 13 685 488 751
FNDX 13 409 2 106 822
CES1.L 13 264 2 041 254
SXRJ.DE 13 264 2 041 254
VOOV 11 883 1 611 691
DFUS 11 828 1 858 415
SMMD 11 282 1 772 627
ESGV 11 067 1 665 804
EZM 10 015 1 496 741
SPTM 9 292 1 429 999
DFAU 9 042 1 420 679
ISCV 8 719 1 341 804
RWL 8 457 1 328 763
XSP.TO 8 317 1 746 300
KOMP 8 247 1 266 493
IDEV 8 150 1 254 240
PRF 8 050 1 264 816
TILT 7 904 1 256 498
VONE 7 859 1 065 916
HTEC 6 885 0
IBCF.DE 6 847 1 053 691
IUSE.L 6 847 1 053 691
IVV.AX 6 796 1 605 407
BSX.PA 6 465 1 027 741
LSK7.DE 6 465 1 027 741
VFVA 6 429 967 693
XUS.TO 6 299 1 322 646
5ESG.L 6 275 985 913
IXJ.AX 6 252 1 477 036
ALTL 6 145 965 502
IEUR 6 129 943 185
WLDS.L 5 785 890 339
WSML.L 5 785 890 339
IUSN.DE 5 785 890 339
5ESGE.MI 5 417 851 104
S5SG.DE 5 417 851 104
IQSM 5 114 803 511
SSO 4 682 735 635
S5SD.DE 4 617 725 396
SMLF 4 387 675 144
FELV 4 231 666 340
VTHR 3 975 539 129
EQAL 3 885 610 411
SCHK 3 691 560 035
SPXL 3 661 576 570
RSPA 3 559 559 190
PTLC 3 226 506 869
PSET 3 217 506 645
XYLD 3 099 492 648
SNPE 2 872 451 248
XHC.TO 2 534 532 151
XEQT.TO 2 322 82 934
SAEF 2 318 348 814
XUU.TO 2 289 498 360
UPRO 2 266 356 033
IYY 2 232 343 464
XEQT.TO 2 223 466 725
SPYX 2 186 335 268
ISCB 2 154 331 523
HIBL 2 075 326 791
XEU.TO 2 074 74 071
XFH.TO 1 992 71 151
SPUS 1 978 310 783
FTXH 1 970 303 183
JHML 1 801 257 687
UC13.L 1 788 280 860
UBU9.DE 1 788 280 860
AVUS 1 759 276 374
GUSA 1 725 271 032
IHVV.AX 1 630 385 112
EFIV 1 524 236 433
L100.L 1 490 236 865
QVML 1 380 216 825
USPG.L 1 215 190 863
XAW.TO 1 206 253 147
IUS 1 184 186 030
UEQD.DE 1 049 164 765
VE.TO 1 039 33 571
CURE 1 030 162 214
FNDB 1 019 154 612
GPIX 987 155 077
HELX 968 143 651
SZNE 957 150 363
S5SD.L 928 145 748
XEH.TO 926 33 058
AVMC 911 143 136
IGUS.L 871 134 057
RSPE 865 135 908
ESPX.AS 847 130 409
CBUM.DE 847 130 409
LSEQ 844 132 921
QDPL 841 132 137
V3AL.L 829 112 437
V3AA.L 829 112 437
ISPY 794 124 753
XAW.TO 776 27 694
V3AB.L 762 13 174
V3AL.L 762 17 906
V3AA.L 762 17 906
V3AM.L 762 13 174
IEUS 733 112 842
SPYI 705 110 769
DXUV 690 108 412
REVS 687 107 941
DFLV 677 106 370
IUSC.SW 664 102 239
GVUS 627 98 514
XWD.TO 604 130 898
VLU 564 87 101
RXL 526 82 645
JUST 471 74 003
IHHY.AX 441 63 163
XVV 426 66 933
DBEZ 413 11 620
R1VL.L 391 60 174
HCMT 359 56 538
XBAL.TO 350 12 645
XBAL.TO 342 74 568
BMED 337 51 849
XUH.TO 327 50 334
SPXT 291 45 721
AVLC 273 42 893
XTR.TO 273 35 147
STXM 251 39 437
USFM.L 216 33 950
USUE.DE 216 33 950
AVSU 188 29 538
SPUU 154 24 253
IE00BHXMHL11.SG 148 23 329
DCOR 145 22 782
PBP 140 21 996
STXG 127 19 954
STXV 100 15 712
BUYO 98 15 398
XSC.TO 90 11 722
ONEO 86 13 214
DEUS 71 11 155
SPXN 70 10 998
GHYC.SW 70 11 134
SPXE 65 10 212
BRTR 60 5 685
PHDG 59 9 270
XYLG 59 9 379
XRMI 57 9 061
LSPX.L 49 7 789
6TVM.DE 49 7 789
ETFSP500.WA 49 7 789
SP5L.L 49 7 789
GHYC.SW 49 7 744
LSPU.L 49 7 789
SP5H.PA 49 7 789
LYP2.DE 49 7 789
SNPV 21 3 299
MMTM 14 2 151
XTR.TO 14 2 147
XCLR 4 635
XTR 2 317
EQL.TO 0 0
PXS.TO 0 0
ESG.TO 0 0
DWSH -971 -152 563
Wiadomości dla Charles River Laboratories International, Inc.
Tytuł Treść Źródło Aktualizacja Link
Deciphering Charles River (CRL) International Revenue Trends Examine the evolution of Charles River's (CRL) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com 2025-02-24 12:15:29 Czytaj oryginał (ang.)
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance On Wednesday, Charles River Laboratories International Inc CRL reported fourth-quarter 2024 revenue of $1 billion, a decrease of 1.1% year over year, beating the consensus of $983.63 million. benzinga.com 2025-02-19 18:58:08 Czytaj oryginał (ang.)
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey Woodring - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded. seekingalpha.com 2025-02-19 17:03:11 Czytaj oryginał (ang.)
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments. zacks.com 2025-02-19 16:55:16 Czytaj oryginał (ang.)
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-19 12:35:37 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.50 per share. This compares to earnings of $2.46 per share a year ago. zacks.com 2025-02-19 11:10:35 Czytaj oryginał (ang.)
Charles River beats quarterly estimates on stable demand for drug development services Charles River Laboratories on Wednesday beat fourth-quarter profit and revenue estimates, helped by stable demand for its drug discovery and development services from biotech clients. reuters.com 2025-02-19 10:11:32 Czytaj oryginał (ang.)
Gear Up for Charles River (CRL) Q4 Earnings: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com 2025-02-17 12:21:22 Czytaj oryginał (ang.)
Is Now the Right Time to Hold on to Charles River Stock? CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors. zacks.com 2025-02-14 08:51:08 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-12 13:06:54 Czytaj oryginał (ang.)
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology. businesswire.com 2025-02-11 10:00:00 Czytaj oryginał (ang.)
CRL Gears Up for Q4 Earnings: Here's What You Need to Know Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues. zacks.com 2025-02-03 10:45:28 Czytaj oryginał (ang.)
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio. zacks.com 2025-01-22 11:21:18 Czytaj oryginał (ang.)
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making. businesswire.com 2025-01-21 10:00:00 Czytaj oryginał (ang.)
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform. zacks.com 2025-01-17 09:16:08 Czytaj oryginał (ang.)
Should You Retain Charles River Stock in Your Portfolio Now? CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors. zacks.com 2025-01-02 10:30:28 Czytaj oryginał (ang.)
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer. zacks.com 2024-12-17 11:25:40 Czytaj oryginał (ang.)
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report? Charles River (CRL) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-09 08:49:31 Czytaj oryginał (ang.)
CRL Stock to Gain From the Global Biotech Incubator Program Launch Charles River's new initiative specifically caters to early-stage biotechnology developers. zacks.com 2024-12-06 11:06:11 Czytaj oryginał (ang.)
Charles River Introduces Global Biotech Incubator Program WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offeri. businesswire.com 2024-12-05 10:00:00 Czytaj oryginał (ang.)
Is it the Right Time to Hold Charles River Stock in Your Portfolio? Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts. zacks.com 2024-11-28 10:21:20 Czytaj oryginał (ang.)
Charles River (CRL) International Revenue in Focus: Trends and Expectations Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. zacks.com 2024-11-11 12:20:49 Czytaj oryginał (ang.)
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs David Windley - Jefferies Group LLC Eric Coldwell - Robert W. Baird & Co. Justin Bowers - Deutsche Bank Dan Leonard - UBS Group AG Elizabeth Anderson - Evercore ISI Michael Ryskin - BofA Securities, Inc. Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Chase & Co. Luke Sergott - Barclays Patrick Donnelly - Citigroup Inc. Operator Please stand by, we're about to begin. seekingalpha.com 2024-11-06 20:51:02 Czytaj oryginał (ang.)
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment. zacks.com 2024-11-06 15:01:18 Czytaj oryginał (ang.)
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-11-06 12:35:40 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago. zacks.com 2024-11-06 11:10:47 Czytaj oryginał (ang.)
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services. reuters.com 2024-11-06 10:30:23 Czytaj oryginał (ang.)
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-30 13:07:36 Czytaj oryginał (ang.)
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2024-10-29 15:10:53 Czytaj oryginał (ang.)
CRL Gears Up for Q3 Earnings: Here's What You Need to Know Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand. zacks.com 2024-10-22 14:30:39 Czytaj oryginał (ang.)
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro. zacks.com 2024-10-18 13:55:28 Czytaj oryginał (ang.)
Charles River Launches New Retrogenix® Non-Human Protein Library WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selection. businesswire.com 2024-10-17 12:00:00 Czytaj oryginał (ang.)
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call. businesswire.com 2024-10-16 20:30:00 Czytaj oryginał (ang.)
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs. zacks.com 2024-10-10 14:10:21 Czytaj oryginał (ang.)
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution. businesswire.com 2024-10-08 15:26:00 Czytaj oryginał (ang.)